It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV.
Identifieur interne : 000487 ( Main/Exploration ); précédent : 000486; suivant : 000488It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV.
Auteurs : Alexander W. Kay [États-Unis] ; Tara E. Ness [États-Unis] ; Leonardo Martinez [États-Unis] ; Anna M. Mandalakas [États-Unis]Source :
- The American journal of tropical medicine and hygiene [ 1476-1645 ] ; 2020.
Descripteurs français
- KwdFr :
- AMP (analogues et dérivés), AMP (usage thérapeutique), Alanine (analogues et dérivés), Alanine (usage thérapeutique), Analyse de survie (MeSH), Antituberculeux (usage thérapeutique), Antiviraux (usage thérapeutique), Betacoronavirus (pathogénicité), Co-infection (MeSH), Comorbidité (MeSH), Humains (MeSH), Infections à VIH (mortalité), Infections à VIH (traitement médicamenteux), Infections à VIH (virologie), Infections à VIH (épidémiologie), Infections à coronavirus (mortalité), Infections à coronavirus (traitement médicamenteux), Infections à coronavirus (virologie), Infections à coronavirus (épidémiologie), Interactions médicamenteuses (MeSH), Mycobacterium tuberculosis (pathogénicité), Pandémies (MeSH), Pneumopathie virale (mortalité), Pneumopathie virale (traitement médicamenteux), Pneumopathie virale (virologie), Pneumopathie virale (épidémiologie), Prévalence (MeSH), Rifampicine (usage thérapeutique), Tuberculose pulmonaire (mortalité), Tuberculose pulmonaire (traitement médicamenteux), Tuberculose pulmonaire (virologie), Tuberculose pulmonaire (épidémiologie), VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité), États-Unis (épidémiologie).
- MESH :
- analogues et dérivés : AMP, Alanine.
- mortalité : Infections à VIH, Infections à coronavirus, Pneumopathie virale, Tuberculose pulmonaire.
- pathogénicité : Betacoronavirus, Mycobacterium tuberculosis, VIH-1 (Virus de l'Immunodéficience Humaine de type 1).
- traitement médicamenteux : Infections à VIH, Infections à coronavirus, Pneumopathie virale, Tuberculose pulmonaire.
- usage thérapeutique : AMP, Alanine, Antituberculeux, Antiviraux, Rifampicine.
- virologie : Infections à VIH, Infections à coronavirus, Pneumopathie virale, Tuberculose pulmonaire.
- épidémiologie : Infections à VIH, Infections à coronavirus, Pneumopathie virale, Tuberculose pulmonaire, États-Unis.
- Analyse de survie, Co-infection, Comorbidité, Humains, Interactions médicamenteuses, Pandémies, Prévalence.
- Wicri :
- geographic : États-Unis.
English descriptors
- KwdEn :
- Adenosine Monophosphate (analogs & derivatives), Adenosine Monophosphate (therapeutic use), Alanine (analogs & derivatives), Alanine (therapeutic use), Antitubercular Agents (therapeutic use), Antiviral Agents (therapeutic use), Betacoronavirus (pathogenicity), COVID-19 (MeSH), Coinfection (MeSH), Comorbidity (MeSH), Coronavirus Infections (drug therapy), Coronavirus Infections (epidemiology), Coronavirus Infections (mortality), Coronavirus Infections (virology), Drug Interactions (MeSH), HIV Infections (drug therapy), HIV Infections (epidemiology), HIV Infections (mortality), HIV Infections (virology), HIV-1 (pathogenicity), Humans (MeSH), Mycobacterium tuberculosis (pathogenicity), Pandemics (MeSH), Pneumonia, Viral (drug therapy), Pneumonia, Viral (epidemiology), Pneumonia, Viral (mortality), Pneumonia, Viral (virology), Prevalence (MeSH), Rifampin (therapeutic use), SARS-CoV-2 (MeSH), Survival Analysis (MeSH), Tuberculosis, Pulmonary (drug therapy), Tuberculosis, Pulmonary (epidemiology), Tuberculosis, Pulmonary (mortality), Tuberculosis, Pulmonary (virology), United States (epidemiology).
- MESH :
- chemical , analogs & derivatives : Adenosine Monophosphate, Alanine.
- chemical , therapeutic use : Adenosine Monophosphate, Alanine, Antitubercular Agents, Antiviral Agents, Rifampin.
- geographic , epidemiology : United States.
- drug therapy : Coronavirus Infections, HIV Infections, Pneumonia, Viral, Tuberculosis, Pulmonary.
- epidemiology : Coronavirus Infections, HIV Infections, Pneumonia, Viral, Tuberculosis, Pulmonary.
- mortality : Coronavirus Infections, HIV Infections, Pneumonia, Viral, Tuberculosis, Pulmonary.
- pathogenicity : Betacoronavirus, HIV-1, Mycobacterium tuberculosis.
- virology : Coronavirus Infections, HIV Infections, Pneumonia, Viral, Tuberculosis, Pulmonary.
- COVID-19, Coinfection, Comorbidity, Drug Interactions, Humans, Pandemics, Prevalence, SARS-CoV-2, Survival Analysis.
DOI: 10.4269/ajtmh.20-1089
PubMed: 32876009
PubMed Central: PMC7543805
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV.</title>
<author><name sortKey="Kay, Alexander W" sort="Kay, Alexander W" uniqKey="Kay A" first="Alexander W" last="Kay">Alexander W. Kay</name>
<affiliation wicri:level="2"><nlm:affiliation>Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Baylor College of Medicine and Texas Children's Hospital, Houston</wicri:cityArea>
</affiliation>
<affiliation><nlm:affiliation>Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini.</nlm:affiliation>
<wicri:noCountry code="subField">Eswatini</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Ness, Tara E" sort="Ness, Tara E" uniqKey="Ness T" first="Tara E" last="Ness">Tara E. Ness</name>
<affiliation wicri:level="2"><nlm:affiliation>Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Baylor College of Medicine and Texas Children's Hospital, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Martinez, Leonardo" sort="Martinez, Leonardo" uniqKey="Martinez L" first="Leonardo" last="Martinez">Leonardo Martinez</name>
<affiliation wicri:level="2"><nlm:affiliation>Stanford University, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Stanford University, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mandalakas, Anna M" sort="Mandalakas, Anna M" uniqKey="Mandalakas A" first="Anna M" last="Mandalakas">Anna M. Mandalakas</name>
<affiliation wicri:level="2"><nlm:affiliation>Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Baylor College of Medicine and Texas Children's Hospital, Houston</wicri:cityArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32876009</idno>
<idno type="pmid">32876009</idno>
<idno type="doi">10.4269/ajtmh.20-1089</idno>
<idno type="pmc">PMC7543805</idno>
<idno type="wicri:Area/Main/Corpus">000357</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000357</idno>
<idno type="wicri:Area/Main/Curation">000357</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000357</idno>
<idno type="wicri:Area/Main/Exploration">000357</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV.</title>
<author><name sortKey="Kay, Alexander W" sort="Kay, Alexander W" uniqKey="Kay A" first="Alexander W" last="Kay">Alexander W. Kay</name>
<affiliation wicri:level="2"><nlm:affiliation>Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Baylor College of Medicine and Texas Children's Hospital, Houston</wicri:cityArea>
</affiliation>
<affiliation><nlm:affiliation>Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini.</nlm:affiliation>
<wicri:noCountry code="subField">Eswatini</wicri:noCountry>
</affiliation>
</author>
<author><name sortKey="Ness, Tara E" sort="Ness, Tara E" uniqKey="Ness T" first="Tara E" last="Ness">Tara E. Ness</name>
<affiliation wicri:level="2"><nlm:affiliation>Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Baylor College of Medicine and Texas Children's Hospital, Houston</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Martinez, Leonardo" sort="Martinez, Leonardo" uniqKey="Martinez L" first="Leonardo" last="Martinez">Leonardo Martinez</name>
<affiliation wicri:level="2"><nlm:affiliation>Stanford University, Stanford, California.</nlm:affiliation>
<country>États-Unis</country>
<placeName><region type="state">Californie</region>
</placeName>
<wicri:cityArea>Stanford University, Stanford</wicri:cityArea>
</affiliation>
</author>
<author><name sortKey="Mandalakas, Anna M" sort="Mandalakas, Anna M" uniqKey="Mandalakas A" first="Anna M" last="Mandalakas">Anna M. Mandalakas</name>
<affiliation wicri:level="2"><nlm:affiliation>Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName><region type="state">Texas</region>
</placeName>
<wicri:cityArea>Baylor College of Medicine and Texas Children's Hospital, Houston</wicri:cityArea>
</affiliation>
</author>
</analytic>
<series><title level="j">The American journal of tropical medicine and hygiene</title>
<idno type="eISSN">1476-1645</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adenosine Monophosphate (analogs & derivatives)</term>
<term>Adenosine Monophosphate (therapeutic use)</term>
<term>Alanine (analogs & derivatives)</term>
<term>Alanine (therapeutic use)</term>
<term>Antitubercular Agents (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>Betacoronavirus (pathogenicity)</term>
<term>COVID-19 (MeSH)</term>
<term>Coinfection (MeSH)</term>
<term>Comorbidity (MeSH)</term>
<term>Coronavirus Infections (drug therapy)</term>
<term>Coronavirus Infections (epidemiology)</term>
<term>Coronavirus Infections (mortality)</term>
<term>Coronavirus Infections (virology)</term>
<term>Drug Interactions (MeSH)</term>
<term>HIV Infections (drug therapy)</term>
<term>HIV Infections (epidemiology)</term>
<term>HIV Infections (mortality)</term>
<term>HIV Infections (virology)</term>
<term>HIV-1 (pathogenicity)</term>
<term>Humans (MeSH)</term>
<term>Mycobacterium tuberculosis (pathogenicity)</term>
<term>Pandemics (MeSH)</term>
<term>Pneumonia, Viral (drug therapy)</term>
<term>Pneumonia, Viral (epidemiology)</term>
<term>Pneumonia, Viral (mortality)</term>
<term>Pneumonia, Viral (virology)</term>
<term>Prevalence (MeSH)</term>
<term>Rifampin (therapeutic use)</term>
<term>SARS-CoV-2 (MeSH)</term>
<term>Survival Analysis (MeSH)</term>
<term>Tuberculosis, Pulmonary (drug therapy)</term>
<term>Tuberculosis, Pulmonary (epidemiology)</term>
<term>Tuberculosis, Pulmonary (mortality)</term>
<term>Tuberculosis, Pulmonary (virology)</term>
<term>United States (epidemiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>AMP (analogues et dérivés)</term>
<term>AMP (usage thérapeutique)</term>
<term>Alanine (analogues et dérivés)</term>
<term>Alanine (usage thérapeutique)</term>
<term>Analyse de survie (MeSH)</term>
<term>Antituberculeux (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Betacoronavirus (pathogénicité)</term>
<term>Co-infection (MeSH)</term>
<term>Comorbidité (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Infections à VIH (mortalité)</term>
<term>Infections à VIH (traitement médicamenteux)</term>
<term>Infections à VIH (virologie)</term>
<term>Infections à VIH (épidémiologie)</term>
<term>Infections à coronavirus (mortalité)</term>
<term>Infections à coronavirus (traitement médicamenteux)</term>
<term>Infections à coronavirus (virologie)</term>
<term>Infections à coronavirus (épidémiologie)</term>
<term>Interactions médicamenteuses (MeSH)</term>
<term>Mycobacterium tuberculosis (pathogénicité)</term>
<term>Pandémies (MeSH)</term>
<term>Pneumopathie virale (mortalité)</term>
<term>Pneumopathie virale (traitement médicamenteux)</term>
<term>Pneumopathie virale (virologie)</term>
<term>Pneumopathie virale (épidémiologie)</term>
<term>Prévalence (MeSH)</term>
<term>Rifampicine (usage thérapeutique)</term>
<term>Tuberculose pulmonaire (mortalité)</term>
<term>Tuberculose pulmonaire (traitement médicamenteux)</term>
<term>Tuberculose pulmonaire (virologie)</term>
<term>Tuberculose pulmonaire (épidémiologie)</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1) (pathogénicité)</term>
<term>États-Unis (épidémiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Adenosine Monophosphate</term>
<term>Alanine</term>
<term>Antitubercular Agents</term>
<term>Antiviral Agents</term>
<term>Rifampin</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en"><term>United States</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Coronavirus Infections</term>
<term>HIV Infections</term>
<term>Pneumonia, Viral</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Coronavirus Infections</term>
<term>HIV Infections</term>
<term>Pneumonia, Viral</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Coronavirus Infections</term>
<term>HIV Infections</term>
<term>Pneumonia, Viral</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="mortalité" xml:lang="fr"><term>Infections à VIH</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Tuberculose pulmonaire</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogenicity" xml:lang="en"><term>Betacoronavirus</term>
<term>HIV-1</term>
<term>Mycobacterium tuberculosis</term>
</keywords>
<keywords scheme="MESH" qualifier="pathogénicité" xml:lang="fr"><term>Betacoronavirus</term>
<term>Mycobacterium tuberculosis</term>
<term>VIH-1 (Virus de l'Immunodéficience Humaine de type 1)</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Infections à VIH</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Tuberculose pulmonaire</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>AMP</term>
<term>Alanine</term>
<term>Antituberculeux</term>
<term>Antiviraux</term>
<term>Rifampicine</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Infections à VIH</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Tuberculose pulmonaire</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Coronavirus Infections</term>
<term>HIV Infections</term>
<term>Pneumonia, Viral</term>
<term>Tuberculosis, Pulmonary</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Infections à VIH</term>
<term>Infections à coronavirus</term>
<term>Pneumopathie virale</term>
<term>Tuberculose pulmonaire</term>
<term>États-Unis</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>COVID-19</term>
<term>Coinfection</term>
<term>Comorbidity</term>
<term>Drug Interactions</term>
<term>Humans</term>
<term>Pandemics</term>
<term>Prevalence</term>
<term>SARS-CoV-2</term>
<term>Survival Analysis</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Analyse de survie</term>
<term>Co-infection</term>
<term>Comorbidité</term>
<term>Humains</term>
<term>Interactions médicamenteuses</term>
<term>Pandémies</term>
<term>Prévalence</term>
</keywords>
<keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>États-Unis</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32876009</PMID>
<DateCompleted><Year>2020</Year>
<Month>10</Month>
<Day>27</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1476-1645</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>103</Volume>
<Issue>4</Issue>
<PubDate><Year>2020</Year>
<Month>10</Month>
</PubDate>
</JournalIssue>
<Title>The American journal of tropical medicine and hygiene</Title>
<ISOAbbreviation>Am J Trop Med Hyg</ISOAbbreviation>
</Journal>
<ArticleTitle>It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV.</ArticleTitle>
<Pagination><MedlinePgn>1348-1349</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.4269/ajtmh.20-1089</ELocationID>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kay</LastName>
<ForeName>Alexander W</ForeName>
<Initials>AW</Initials>
<AffiliationInfo><Affiliation>Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Baylor College of Medicine Children's Foundation Eswatini, Mbabane, Eswatini.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Ness</LastName>
<ForeName>Tara E</ForeName>
<Initials>TE</Initials>
<AffiliationInfo><Affiliation>Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martinez</LastName>
<ForeName>Leonardo</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Stanford University, Stanford, California.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Mandalakas</LastName>
<ForeName>Anna M</ForeName>
<Initials>AM</Initials>
<AffiliationInfo><Affiliation>Baylor College of Medicine and Texas Children's Hospital, Houston, Texas.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016421">Editorial</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Am J Trop Med Hyg</MedlineTA>
<NlmUniqueID>0370507</NlmUniqueID>
<ISSNLinking>0002-9637</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000995">Antitubercular Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>3QKI37EEHE</RegistryNumber>
<NameOfSubstance UI="C000606551">remdesivir</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>415SHH325A</RegistryNumber>
<NameOfSubstance UI="D000249">Adenosine Monophosphate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>OF5P57N2ZX</RegistryNumber>
<NameOfSubstance UI="D000409">Alanine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VJT6J7R4TR</RegistryNumber>
<NameOfSubstance UI="D012293">Rifampin</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>AIM</CitationSubset>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000249" MajorTopicYN="N">Adenosine Monophosphate</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000409" MajorTopicYN="N">Alanine</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000995" MajorTopicYN="N">Antitubercular Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000073640" MajorTopicYN="N">Betacoronavirus</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D060085" MajorTopicYN="N">Coinfection</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004347" MajorTopicYN="N">Drug Interactions</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015497" MajorTopicYN="N">HIV-1</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009169" MajorTopicYN="N">Mycobacterium tuberculosis</DescriptorName>
<QualifierName UI="Q000472" MajorTopicYN="Y">pathogenicity</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="Y">Pandemics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012293" MajorTopicYN="N">Rifampin</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014397" MajorTopicYN="N">Tuberculosis, Pulmonary</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>9</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>10</Month>
<Day>28</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>9</Month>
<Day>3</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32876009</ArticleId>
<ArticleId IdType="doi">10.4269/ajtmh.20-1089</ArticleId>
<ArticleId IdType="pmc">PMC7543805</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Med Virol. 2020 Oct;92(10):1777-1778</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32293709</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AIDS Patient Care STDS. 2020 Jun;34(6):247-248</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32407127</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS One. 2017 Aug 1;12(8):e0182185</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28763500</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet HIV. 2020 Aug;7(8):e554-e564</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32473657</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Nov 19;71(16):2294-2297</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32472138</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2020 Nov 19;71(16):2276-2278</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32407467</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Aug;584(7821):430-436</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32640463</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Glob Health. 2020 Sep;8(9):e1132-e1141</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32673577</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Sep;8(9):844-846</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32758439</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Jun;8(6):536-538</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32220280</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Emerg Infect Dis. 2020 Oct;26(10):2506-2508</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32672531</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pulmonology. 2020 Jul - Aug;26(4):233-240</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32411943</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Texas</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Texas"><name sortKey="Kay, Alexander W" sort="Kay, Alexander W" uniqKey="Kay A" first="Alexander W" last="Kay">Alexander W. Kay</name>
</region>
<name sortKey="Mandalakas, Anna M" sort="Mandalakas, Anna M" uniqKey="Mandalakas A" first="Anna M" last="Mandalakas">Anna M. Mandalakas</name>
<name sortKey="Martinez, Leonardo" sort="Martinez, Leonardo" uniqKey="Martinez L" first="Leonardo" last="Martinez">Leonardo Martinez</name>
<name sortKey="Ness, Tara E" sort="Ness, Tara E" uniqKey="Ness T" first="Tara E" last="Ness">Tara E. Ness</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000487 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000487 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= CovidStanfordV1 |flux= Main |étape= Exploration |type= RBID |clé= pubmed:32876009 |texte= It Ain't Over Till It's Over: The Triple Threat of COVID-19, TB, and HIV. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32876009" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \ | NlmPubMed2Wicri -a CovidStanfordV1
This area was generated with Dilib version V0.6.38. |